The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium
出版年份 2017 全文链接
标题
The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume 18, Issue 18, Pages 1929-1938
出版商
Informa UK Limited
发表日期
2017-11-14
DOI
10.1080/14656566.2017.1404574
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
- (2017) Srdan Verstovsek et al. LEUKEMIA RESEARCH
- Ruxolitinib for the management of myelofibrosis: Results of an international physician survey
- (2017) Martin H. Ellis et al. LEUKEMIA RESEARCH
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN
- (2016) Massimo Breccia et al. ANNALS OF HEMATOLOGY
- Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL
- (2016) N. Daver et al. BLOOD
- Does ruxolitinib prolong the survival of patients with myelofibrosis?
- (2016) Francisco Cervantes et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)
- (2016) Ruben Mesa et al. BRITISH JOURNAL OF HAEMATOLOGY
- The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
- (2016) V. Gupta et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Ruxolitinib dose management as a key to long-term treatment success
- (2016) Ruben A. Mesa et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
- (2016) Srdan Verstovsek et al. Journal of Hematology & Oncology
- A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
- (2016) S Verstovsek et al. LEUKEMIA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations
- (2016) M Marchetti et al. LEUKEMIA
- Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
- (2016) Claire N. Harrison et al. LEUKEMIA & LYMPHOMA
- Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
- (2016) Guido Lancman et al. Expert Review of Hematology
- The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
- (2016) V. Gupta et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms
- (2016) Jason B. Kaplan et al. EBioMedicine
- Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management
- (2015) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Rasburicase-induced Heinz body hemolytic anemia in a patient with chronic lymphocytic leukemia
- (2015) M. A. Hrisinko et al. BLOOD
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
- (2015) R. S. Komrokji et al. BLOOD
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
- (2015) Sara C. Meyer et al. CANCER CELL
- JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
- (2015) Kathrin Schönberg et al. CANCER RESEARCH
- Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
- (2015) Ruben A. Mesa et al. Clinical Lymphoma Myeloma & Leukemia
- Pathogenesis of myeloproliferative neoplasms
- (2015) Radek C. Skoda et al. EXPERIMENTAL HEMATOLOGY
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
- (2015) N M Kröger et al. LEUKEMIA
- Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis
- (2015) John Mascarenhas LEUKEMIA & LYMPHOMA
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
- (2014) A. Tefferi et al. BLOOD
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasms
- (2014) Allison Rosenthal et al. EXPERT OPINION ON PHARMACOTHERAPY
- Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?
- (2014) G Barosi et al. LEUKEMIA
- Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
- (2014) G Barosi et al. LEUKEMIA
- Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis
- (2014) Y Nakaya et al. Blood Cancer Journal
- Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap
- (2012) Camelia Iancu-Rubin et al. EXPERIMENTAL HEMATOLOGY
- Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)
- (2012) Anders Poulsen et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
- (2011) Alfonso Quintás-Cardama et al. NATURE REVIEWS DRUG DISCOVERY
- Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans
- (2010) A. D. Shilling et al. DRUG METABOLISM AND DISPOSITION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now